Role of enhanced half-life factor VIII and IX in the treatment of haemophilia (Q38371071)

2 September 2017

1 reference

title

Role of enhanced half-life factor VIII and IX in the treatment of haemophilia (English)

1 reference

2 September 2017

0 references

Coagulation factor VIII

0 references

coagulation factor IX

0 references

author name string

Ali J Mahdi

series ordinal

1

1 reference

2 September 2017

Samya G Obaji

series ordinal

2

1 reference

2 September 2017

Peter W Collins

series ordinal

3

1 reference

2 September 2017

language of work or name

English

0 references

publication date

7 March 2015

1 reference

British Journal of Haematology

2 September 2017

1 reference

2 September 2017

169

1 reference

2 September 2017

768-776

1 reference

2 September 2017

6

1 reference

Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs

2 September 2017

1 reference

Population pharmacokinetics of recombinant factor IX: implications for dose tailoring

21 January 2018

1 reference

Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.

21 January 2018

1 reference

Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring

21 January 2018

1 reference

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

21 January 2018

1 reference

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

21 January 2018

1 reference

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial

21 January 2018

1 reference

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.

21 January 2018

1 reference

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

21 January 2018

1 reference

Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients

21 January 2018

1 reference

The principal results of the International Immune Tolerance Study: a randomized dose comparison

21 January 2018

1 reference

A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.

21 January 2018

1 reference

Clearance mechanisms of von Willebrand factor and factor VIII.

21 January 2018

1 reference

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

21 January 2018

1 reference

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

21 January 2018

1 reference

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

21 January 2018

1 reference

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.

21 January 2018

1 reference

Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs

21 January 2018

1 reference

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

21 January 2018

1 reference

Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice

21 January 2018

1 reference

Prolonged activity of factor IX as a monomeric Fc fusion protein

21 January 2018

1 reference

Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein

21 January 2018

1 reference

Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.

21 January 2018

1 reference

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

21 January 2018

1 reference

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

21 January 2018

1 reference

Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.

21 January 2018

1 reference

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

21 January 2018

1 reference

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

21 January 2018

1 reference

A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models

21 January 2018

1 reference

Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.

21 January 2018

1 reference

The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.13360

1 reference

2 September 2017

1 reference